From 2D To Organ-On-A-Chip: Platforms Powering Modern Disease Models

Animal models no longer define the ceiling of disease research. The past decade has produced a toolkit spanning 2D cell cultures, 3D organoids, and organ-on-a-chip systems, and selecting among them requires more than familiarity with the technology. It requires understanding where each platform breaks down. Flat cell cultures remain workhorses for early-stage screening, but their inability to replicate tissue architecture limits translational relevance. Organoids restore some of that complexity, yet reproducibility and vascularization remain persistent challenges. Organ-on-a-chip systems add dynamic flow and mechanical cues, bringing models closer to physiological reality, though scaling and standardization are still maturing

 Regulatory shifts, including the FDA's 2025 relaxation of mandatory animal testing requirements, are accelerating adoption of these alternatives across the industry. Read the full article to understand which platform fits which research question.